Weighted scores for etravirine susceptibility

Monogram		Janssen Therapeutics (Tibotec)
Weight	Mutations	Weight	Mutations
4	100I, 101P, 181C/I	3	181I/V
3	138A/G, 179E, 190Q, 230L, 238N	2.5	101P, 100I, 181C, 230L
2	101E, 106A, 138K, 179L, 188L	1.5	138A, 106I, 190S, 179F
1	90I, 101H, 106M, 138Q, 179D/F/M, 181F, 190E/T, 221Y, 225H, 238T	1	90I, 179D, 101E, 101H, 98G, 179T, 190A
Total score*:		Total score^¶:
≥4 = reduced susceptibility		0-2: Susceptible
		2.5-3.5: Intermediate
		≥4: Resistant

Weighted scoring systems for determining etravirine susceptibility based on genotype analysis. The score is determined by adding the weights for each mutation present.

* The Monogram system (left) predicts phenotypic susceptibility.
¶ The Janssen Therapeutics (Tibotec) system (right) predicts virologic response in the DUET trials:

0-2 = 74 percent response.
2.5-3.5 = 52 percent response.
≥4 = 38 percent response.

Data from:

Tibotec system: Vingerhoets, J, Peeters, M, Azijn, H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Program and abstracts of the XVII International HIV Drug Resistance Workshop; Sitges, Spain; June 10-14, 2008; Vol. Abstract 24.
Monogram system: Benhamida, J, Chappey, C, Coakley, E, Parkin, NT. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Program and abstracts of the XVII International HIV Drug Resistance Workshop; Sitges, Spain; June 10-14, 2008; Vol. Abstract 130.

Graphic 55515 Version 6.0

خرید پکیج

Weighted scores for etravirine susceptibility